U.S. markets close in 6 minutes

ESSA Pharma Inc. (EPIX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
25.00+0.18 (+0.73%)
As of 3:54PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close24.82
Open24.61
Bid24.77 x 1300
Ask25.19 x 800
Day's Range23.30 - 25.87
52 Week Range3.76 - 32.69
Volume126,671
Avg. Volume357,235
Market Cap983.39M
Beta (5Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-0.99
Earnings DateFeb 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference
    PR Newswire

    ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference

    ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Dr. David R. Parkinson, Chief Executive Officer of ESSA Pharma, will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference, taking place virtually April 20-21, 2021. Dr. Parkinson, along with Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be available for one-on-one meetings.

  • EPIX: Additional Preclinical Data Shows EPI-7386 Inhibits AR-Driven Transcription…
    Zacks Small Cap Research

    EPIX: Additional Preclinical Data Shows EPI-7386 Inhibits AR-Driven Transcription…

    By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Additional Preclinical Data Presented at AACR 2021 On April 10, 2021, ESSA Pharma, Inc. (NASDAQ:EPIX) announced the presentation of encouraging preclinical data at the 2021 American Association of Cancer Research (AACR) annual meeting. A copy of the presentation can be found here . The data presented by ESSA builds

  • ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting
    CNW Group

    ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting

    ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead product candidate, EPI-7386, at the 2021 American Association of Cancer Research (AACR) Annual Meeting, which is taking place virtually April 10-15, 2021. EPI-7386 is an investigational, highly selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor, which exhibits high potency, low metabolism and on-target specificity.